CHICAGO–(BUSINESS WIRE)–Family Medicine Specialists has selected Cardio Diagnostics’ tests to identify patients at risk for coronary heart disease events.
Author: Ken Dropiewski
Nuevocor presents pre-clinical data at ESGCT and AHA meetings
SINGAPORE, Nov. 7, 2023 /PRNewswire/ — Nuevocor, a pre-clinical stage biotechnology company focused on developing cardiac genetic medicines through a unique platform to understand the mechanobiological causes of disease, announced today a pair of presentations at two major meetings, the…
HeartBeam Granted Third US Patent for 12-Lead Extended Wear Patch for Detecting Heart Attacks and Complex Cardiac Arrythmias
SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam Granted Third US Patent for 12-Lead Extended Wear Patch for Detecting Heart Attacks and Complex Cardiac Arrythmias
BioSig Appoints Global MedTech Leader Fred Hrkac as New Executive VP
32-year career in medical device and electrophysiology business expansion for industry bellwethers; led multiple company exits including a $1B sale in 2018 Part of leadership team that grew Johnson & Johnson’s original cardiology/electrophysiology business from $22M to $500M in 7 years Westport, CT, Nov. 07, 2023 (GLOBE NEWSWIRE) — Westport, […]
Cardurion Pharmaceuticals to Provide Update on CaMKII Inhibitor Program at the American Heart Association’s Scientific Sessions 2023
BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced that the Company will present preclinical data on its Calcium/Calmodulin-dependent Protein Kinase II (CaMKII) inhibitor program at the American Heart Association’s (AHA) Scientific Sessions 2023. Cardurion is the first
ResoTher Pharma receives a €2.5 million grant from European Innovation Council (EIC) to support a Phase 2a clinical study of their Lead Candidate RTP-026 for Myocardial Infarction
HOLTE, Denmark, Nov. 6, 2023 /PRNewswire/ — ResoTher Pharma, a biotech company focused on developing life-saving options for patients suffering from cardiovascular disease, today announced that the company has received a €2.5 million grant from the European Innovation Council (EIC) to…
Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023
PRINCETON, N.J.–(BUSINESS WIRE)—- $BMY #BMS–Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023
Stryker reports third quarter 2023 operating results
Kalamazoo, Michigan, Nov. 02, 2023 (GLOBE NEWSWIRE) — Stryker (NYSE:SYK) reported operating results for the third quarter of 2023: Third Quarter Results Reported net sales increased 9.6% to $4.9 billion Organic net sales increased 9.2% Reported operating income margin of 19.0% Adjusted operating income margin(1) increased 110 bps to 23.4% […]
Acutus Medical to Announce Third Quarter 2023 Financial Results
CARLSBAD, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its third quarter 2023 financial results on Monday, November 13, 2023. In conjunction with the […]
MyOme Presents New Data: Improved 10-year Risk Prediction of Coronary Artery Disease through Polygenic Risk Scores Integrated with Clinical Factors Showcased at the American Society of Human Genetics Annual Meeting
Integrated polygenic risk score more accurately identified individuals at elevated risk for developing coronary artery disease, especially within borderline or intermediate clinical risk categories and for South Asian individuals MENLO PARK, Calif., Nov. 2, 2023 /PRNewswire/ — MyOme, Inc….
Recent
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million
BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways
Stryker completes acquisition of Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
Popular
- No commented posts yet